Goldman Has Buy On Pharmaceutical Product Dev. (PPDI)

Goldman Sachs has a Buy rating and a $33 price target on shares of Pharmaceutical Product Dev. (NASDAQ:
PPDI
Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.